Resumen
Lack of guidance and regulation for authorizing medical cannabis for conditions involving the health and neurodevelopment of children is ethically problematic as it promulgates access inequities, risk-benefit inconsistencies, and inadequate consent mechanisms. In two virtual sessions using participatory action research and consensus-building methods, we obtained perspectives of stakeholders on ethics and medical cannabis for children and youth. The sessions focused on the scientific and regulatory landscape of medical cannabis, surrogate decision-making and assent, and the social and political culture of medical cannabis. We found that evidence-gathering and data dissemination, pressures on clinical relationships, and the lack of integration of culturally diverse perspectives and Indigenous knowledges were key areas of concern. Participants emphasized the importance of utilizing adaptive study designs, highlighted the importance of trust-building between clinicians, patients and caregivers, and discussed barriers including historical and ongoing stigmatization of medical cannabis. We conclude that continued public consultation and strength-based research that integrate diverse perspectives are critical steps forward.
Idioma original | English |
---|---|
Número de artículo | 3 |
Publicación | Neuroethics |
Volumen | 15 |
N.º | 1 |
DOI | |
Estado | Published - abr. 2022 |
Nota bibliográfica
Funding Information:Cannabis for Symptom Management in Children with Cancer: Canadian Childhood Cannabinoid Clinical Trials (C4T) Platform (CIHR 707031 ; L. Kelly, Principal Investigator). JI is UBC Distinguished University Scholar. We thank all participants - members of the public and experts - for their time and contributions to this work, and Tracy Brace for her special contribution to the title.
Publisher Copyright:
© 2022, The Author(s), under exclusive licence to Springer Nature B.V.
ASJC Scopus Subject Areas
- Neurology
- Health Policy
- Psychiatry and Mental health